Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOrthopedics/MusculoskeletalHMSA Hyaluronate Coverage Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentHawaii Medical Service Association (HMSA)Policy N/A

    Hyaluronate Products

    Customize your policy alerts

    Sign up for all Hawaii Medical Service Association (HMSA) policy alerts

    Know when Hawaii Medical Service Association (HMSA) releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    HMSA coverage and prior authorization for intra-articular hyaluronate products used to treat knee osteoarthritis pain across HMO, PPO, and QUEST lines of business.

    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyHyaluronate Products
    Policy CodePolicy N/A
    Change TypeProduct addedcoverage requirement removed
    Effective DateJun 26, 2026
    Last ReviewApr 1, 2026
    Next Review DateN/A
    Key ActionObtain precertification for hyaluronate products using the HMSA medical specialty drug policy fax form.
    SourceLink
    POLICY UPDATE CHANGES

    Hymovis One was added to the list of covered hyaluronate products in April 2026.

    The policy history records removal of the corticosteroid injection trial as a coverage requirement effective February 17, 2020.

    17Hyaluronate products listed
    6 monthsConservative therapy before initial approval

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6 monthsInterval before next course
    1 courseInitial authorization
    3-5 injectionsSelected course range

    Medical Necessity and Authorization Criteria

    Initial therapy for knee osteoarthritis

    One course may be authorized when ALL of the following are met:

    Initial therapy requirements

    • Indication

      • The member has osteoarthritis of the knee and is seeking treatment for knee pain.

        Treatment is for pain associated with knee osteoarthritis.

    • Conservative and pharmacologic therapy

      • The member had an inadequate response to six months of conservative therapy.6 months
      • The member had an inadequate response to non-drug therapy, consisting of an exercise program and strength training and/or physical therapy, with counseling regarding weight management if appropriate.
      • ONE of

        • The member had an inadequate response to treatment with acetaminophen, an oral or topical NSAID, or tramadol.
        • The member has a contraindication or history of intolerance to acetaminophen, NSAIDs, or tramadol.

    Second course with a different hyaluronate

    A second course within six months may be granted only when the member cannot complete the previously approved course because of an adverse or allergic reaction.

    Early switch exception

    • The requested product is a different hyaluronate.
    • The request is for a second course within six months.Within 6 months
    • The member was unable to complete the previously approved course because of an adverse or allergic reaction.

    Continuation and reauthorization

    Continuation or reauthorization is covered when the applicable prior-treatment and benefit requirements are met.

    Continuation pathway

    • No previous authorization or precertification

      • The member, including a new member or a member currently receiving treatment without prior authorization, meets all criteria for initial approval.
    • Reauthorization requirements

      • The member previously received a course of intra-articular hyaluronate treatment for the knee joint that was approved by HMSA/CVS.
      • There is evidence of benefit from the previous therapy.
      • The next treatment course with the requested product is planned at least six months after the date of the last injection of the previous completed treatment course.

    Authorization, Documentation, and Billing Requirements

    Prior Authorization

    Precertification Required

    Precertification is required before hyaluronate therapy is reviewed. Submit the request using the HMSA medical specialty drug policy fax form available on the HMSA medical specialty drug policy website.

    Billing Rule

    Medicare Advantage Part B Billing

    For HMSA Medicare Advantage members, office-administered hyaluronate acid injections must be billed by a contracted Medicare Part B provider as a medical claim. A pharmacy cannot bill for these injections.

    Step Therapy

    Therapy Overview

    Intra-articular hyaluronate products are injections used to treat pain associated with osteoarthritis of the knee. This policy applies to HMSA members in the HMO, PPO, and QUEST lines of business and addresses coverage when knee pain has not responded adequately to conservative therapy, non-drug treatment, and simple analgesics such as acetaminophen. Initial approval requires an inadequate response to 6 months of conservative therapy and the applicable non-drug and pharmacologic treatments, unless those treatments are contraindicated or not tolerated.

    Indication and Clinical Terms

    FDA-approved indication
    ConditionPainful osteoarthritis of the knee
    Required responseFailed to respond adequately to conservative non-pharmacologic therapy and simple analgesics
    Example of simple analgesicAcetaminophen
    Contraindication to NSAIDs
    Intolerance or adverse eventHistory of intolerance or adverse event
    HypersensitivityHypersensitivity
    Drug interactionSignificant drug interaction
    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyHyaluronate Products
    Policy CodePolicy N/A
    Change TypeProduct addedcoverage requirement removed
    Effective DateJun 26, 2026
    Last ReviewApr 1, 2026
    Next Review DateN/A
    Key ActionObtain precertification for hyaluronate products using the HMSA medical specialty drug policy fax form.
    SourceLink
    On This Page
    Medical Necessity and Authorization CriteriaAuthorization, Documentation, and Billing RequirementsTherapy OverviewIndication and Clinical Terms
    At least 6 months after the last injection
  1. The member experienced pain relief from the previous course of treatment.
  2. Conservative and Pharmacologic Therapy Required

    Before initial approval, document that the member had an inadequate response to the required conservative and non-drug therapies and to qualifying pharmacologic therapy, unless the pharmacologic therapy was contraindicated or not tolerated.

    • Inadequate response to 6 months of conservative therapy.
    • Inadequate response to an exercise program and strength training and/or physical therapy, with counseling regarding weight management when appropriate.
    • Inadequate response to acetaminophen, an oral or topical NSAID, or tramadol; alternatively, a contraindication or history of intolerance to these treatments.
    Documentation Required

    Document Prior Pharmacologic Treatment

    For an initial-therapy request, provide the names of previous pharmacologic treatments and document inadequate response, intolerance, or contraindication to those treatments.

    • Examples include acetaminophen, NSAIDs, and tramadol.
    Documentation Required

    Document Last Hyaluronate Injection Date

    For continuation therapy, provide the date of the last injection from the member’s previous completed intra-articular hyaluronate treatment course.

    Documentation Required

    Evidence of Benefit Required for Reauthorization

    Reauthorization requires evidence that the member previously received an HMSA/CVS-approved course of intra-articular hyaluronate for the knee and experienced clinically meaningful benefit, including pain relief.

    • The next course must be planned at least 6 months after the last injection of the previous completed course.
    • Document pain relief from the previous course.
    Denial Risk

    Failure to Meet Initial Medical Necessity Criteria

    An initial request may be denied when the member does not meet every medical-necessity requirement for the first course of therapy. The record must support inadequate response to the required conservative, non-drug, and pharmacologic therapies, or a qualifying contraindication or intolerance to the pharmacologic options.

    • Inadequate response to 6 months of conservative therapy is required.
    • Inadequate response to exercise/strength training and/or physical therapy, with weight-management counseling when appropriate, is required.
    • Inadequate response to acetaminophen, an oral or topical NSAID, or tramadol is required unless contraindication or intolerance is documented.
    Denial Risk

    Continuation Criteria Not Met

    A continuation request may be denied when the prior treatment course was not previously approved by HMSA/CVS, the next course is scheduled too soon, or the member did not benefit from the previous course.

    • The next course must begin at least 6 months after the last injection of the previous completed course.
    • Document pain relief from the previous course.
    Denial Risk

    Early Switch Requires Qualifying Reaction

    A second course using a different hyaluronate within six months is only eligible when the member could not complete the previously approved course because of an adverse or allergic reaction.

    • A routine product switch within six months without a qualifying adverse or allergic reaction may be denied.